Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Health information exchange between hospital and skilled nursing facilities not associated with lower readmissions.

Cross DA, McCullough JS, Banaszak-Holl J, Adler-Milstein J.

Health Serv Res. 2019 Dec;54(6):1335-1345. doi: 10.1111/1475-6773.13210. Epub 2019 Oct 10.

PMID:
31602639
2.

Mechanisms of laser-induced damage in absorbing glasses with nanosecond pulses.

Demos SG, Hoffman BN, Carr CW, Cross DA, Negres RA, Bude JD.

Opt Express. 2019 Apr 1;27(7):9975-9986. doi: 10.1364/OE.27.009975.

PMID:
31045145
3.

Drivers of health information exchange use during postacute care transitions.

Cross DA, McCullough JS, Adler-Milstein J.

Am J Manag Care. 2019 Jan 1;25(1):e7-e13.

4.

Mind the gap: the potential of alternative health information exchange.

Everson J, Cross DA.

Am J Manag Care. 2019 Jan;25(1):32-38.

5.

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.

Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG.

J Thorac Oncol. 2018 Dec;13(12):1818-1831. doi: 10.1016/j.jtho.2018.09.017. Epub 2018 Sep 27. Review.

PMID:
30268698
6.

Practice strategies to improve primary care for chronic disease patients under a pay-for-value program.

Cross DA, Nong P, Harris-Lemak C, Cohen GR, Linden A, Adler-Milstein J.

Healthc (Amst). 2019 Mar;7(1):30-37. doi: 10.1016/j.hjdsi.2018.08.004. Epub 2018 Sep 7.

PMID:
30197304
7.

Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors.

Ménard L, Floc'h N, Martin MJ, Cross DAE.

Cancer Res. 2018 Jun 15;78(12):3267-3279. doi: 10.1158/0008-5472.CAN-17-2195. Epub 2018 Mar 19.

8.

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.

Floc'h N, Martin MJ, Riess JW, Orme JP, Staniszewska AD, Ménard L, Cuomo ME, O'Neill DJ, Ward RA, Finlay MRV, McKerrecher D, Cheng M, Vang DP, Burich RA, Keck JG, Gandara DR, Mack PC, Cross DAE.

Mol Cancer Ther. 2018 May;17(5):885-896. doi: 10.1158/1535-7163.MCT-17-0758. Epub 2018 Feb 26.

9.

Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib.

Liu S, Li S, Hai J, Wang X, Chen T, Quinn MM, Gao P, Zhang Y, Ji H, Cross DAE, Wong KK.

Clin Cancer Res. 2018 Jun 1;24(11):2594-2604. doi: 10.1158/1078-0432.CCR-17-1875. Epub 2018 Jan 3.

10.

Mechanisms of surface contamination in fused silica by means of laser-induced electrostatic effects.

Demos SG, Carr CW, Cross DA.

Opt Lett. 2017 Jul 1;42(13):2643-2646. doi: 10.1364/OL.42.002643.

PMID:
28957305
11.

The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M.

Butterworth S, Cross DAE, Finlay MRV, Ward RA, Waring MJ.

Medchemcomm. 2017 May 10;8(5):820-822. doi: 10.1039/c7md90012k. eCollection 2017 May 1.

12.

Outcomes For High-Needs Patients: Practices With A Higher Proportion Of These Patients Have An Edge.

Cross DA, Cohen GR, Lemak CH, Adler-Milstein J.

Health Aff (Millwood). 2017 Mar 1;36(3):476-484. doi: 10.1377/hlthaff.2016.1309.

PMID:
28264949
13.

Sustained participation in a pay-for-value program: impact on high-need patients.

Cross DA, Cohen GR, Harris Lemak C, Adler-Milstein J.

Am J Manag Care. 2017 Feb 1;23(2):e33-e40.

14.

Investing in Post-Acute Care Transitions: Electronic Information Exchange Between Hospitals and Long-Term Care Facilities.

Cross DA, Adler-Milstein J.

J Am Med Dir Assoc. 2017 Jan;18(1):30-34. doi: 10.1016/j.jamda.2016.07.024. Epub 2016 Sep 14.

PMID:
27639335
15.

Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation.

Hennessy EJ, Chuaqui C, Ashton S, Colclough N, Cross DA, Debreczeni JÉ, Eberlein C, Gingipalli L, Klinowska TC, Orme JP, Sha L, Wu X.

ACS Med Chem Lett. 2016 Mar 21;7(5):514-9. doi: 10.1021/acsmedchemlett.6b00058. eCollection 2016 May 12.

16.

Picosecond laser damage performance assessment of multilayer dielectric gratings in vacuum.

Alessi DA, Carr CW, Hackel RP, Negres RA, Stanion K, Fair JE, Cross DA, Nissen J, Luthi R, Guss G, Britten JA, Gourdin WH, Haefner C.

Opt Express. 2015 Jun 15;23(12):15532-44. doi: 10.1364/OE.23.015532.

PMID:
26193533
17.

Assessing payer perspectives on health information exchange.

Cross DA, Lin SC, Adler-Milstein J.

J Am Med Inform Assoc. 2016 Mar;23(2):297-303. doi: 10.1093/jamia/ocv072. Epub 2015 Jul 3.

18.

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.

Eberlein CA, Stetson D, Markovets AA, Al-Kadhimi KJ, Lai Z, Fisher PR, Meador CB, Spitzler P, Ichihara E, Ross SJ, Ahdesmaki MJ, Ahmed A, Ratcliffe LE, O'Brien EL, Barnes CH, Brown H, Smith PD, Dry JR, Beran G, Thress KS, Dougherty B, Pao W, Cross DA.

Cancer Res. 2015 Jun 15;75(12):2489-500. doi: 10.1158/0008-5472.CAN-14-3167. Epub 2015 Apr 13.

19.

Electronic health records and support for primary care teamwork.

O'Malley AS, Draper K, Gourevitch R, Cross DA, Scholle SH.

J Am Med Inform Assoc. 2015 Mar;22(2):426-34. doi: 10.1093/jamia/ocu029. Epub 2015 Jan 27.

20.

Improving EHR Capabilities to Facilitate Stage 3 Meaningful Use Care Coordination Criteria.

Cross DA, Cohen GR, Nong P, Day AV, Vibbert D, Naraharisetti R, Adler-Milstein J.

AMIA Annu Symp Proc. 2015 Nov 5;2015:448-55. eCollection 2015.

21.

Identification of novel vascular targets in lung cancer.

Zhuang X, Herbert JM, Lodhia P, Bradford J, Turner AM, Newby PM, Thickett D, Naidu U, Blakey D, Barry S, Cross DA, Bicknell R.

Br J Cancer. 2015 Feb 3;112(3):485-94. doi: 10.1038/bjc.2014.626. Epub 2014 Dec 23.

22.

Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.

Meador CB, Jin H, de Stanchina E, Nebhan CA, Pirazzoli V, Wang L, Lu P, Vuong H, Hutchinson KE, Jia P, Chen X, Eisenberg R, Ladanyi M, Politi K, Zhao Z, Lovly CM, Cross DA, Pao W.

Mol Cancer Ther. 2015 Feb;14(2):542-52. doi: 10.1158/1535-7163.MCT-14-0723. Epub 2014 Dec 4.

23.

Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.

Finlay MR, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, Bradbury RH, Brown SJ, Butterworth S, Campbell A, Chorley C, Colclough N, Cross DA, Currie GS, Grist M, Hassall L, Hill GB, James D, James M, Kemmitt P, Klinowska T, Lamont G, Lamont SG, Martin N, McFarland HL, Mellor MJ, Orme JP, Perkins D, Perkins P, Richmond G, Smith P, Ward RA, Waring MJ, Whittaker D, Wells S, Wrigley GL.

J Med Chem. 2014 Oct 23;57(20):8249-67. doi: 10.1021/jm500973a. Epub 2014 Oct 1.

PMID:
25271963
24.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W.

Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3.

25.

Growth model for laser-induced damage on the exit surface of fused silica under UV, ns laser irradiation.

Negres RA, Cross DA, Liao ZM, Matthews MJ, Carr CW.

Opt Express. 2014 Feb 24;22(4):3824-44. doi: 10.1364/OE.22.003824.

PMID:
24663703
26.

Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).

Ward RA, Anderton MJ, Ashton S, Bethel PA, Box M, Butterworth S, Colclough N, Chorley CG, Chuaqui C, Cross DA, Dakin LA, Debreczeni JÉ, Eberlein C, Finlay MR, Hill GB, Grist M, Klinowska TC, Lane C, Martin S, Orme JP, Smith P, Wang F, Waring MJ.

J Med Chem. 2013 Sep 12;56(17):7025-48. doi: 10.1021/jm400822z. Epub 2013 Aug 30.

PMID:
23930994
27.

Predictive modeling techniques for nanosecond-laser damage growth in fused silica optics.

Liao ZM, Abdulla GM, Negres RA, Cross DA, Carr CW.

Opt Express. 2012 Jul 2;20(14):15569-79. doi: 10.1364/OE.20.015569.

PMID:
22772252
28.

Probability of growth of small damage sites on the exit surface of fused silica optics.

Negres RA, Abdulla GM, Cross DA, Liao ZM, Carr CW.

Opt Express. 2012 Jun 4;20(12):13030-9. doi: 10.1364/OE.20.013030.

PMID:
22714330
29.

Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 1.

Delouvrié B, Al-Kadhimi K, Arnould JC, Barry ST, Cross DA, Didelot M, Gavine PR, Germain H, Harris CS, Hughes AM, Jude DA, Kendrew J, Lambert-van der Brempt C, Lohmann JJ, Ménard M, Mortlock AA, Pass M, Rooney C, Vautier M, Vincent JL, Warin N.

Bioorg Med Chem Lett. 2012 Jun 15;22(12):4111-6. doi: 10.1016/j.bmcl.2012.04.063. Epub 2012 Apr 21.

PMID:
22575869
30.

Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 2.

Delouvrié B, Al-Kadhimi K, Arnould JC, Barry ST, Cross DA, Didelot M, Gavine PR, Germain H, Harris CS, Hughes AM, Jude DA, Kendrew J, Lambert-van der Brempt C, Lohmann JJ, Ménard M, Mortlock AA, Pass M, Rooney C, Vautier M, Vincent JL, Warin N.

Bioorg Med Chem Lett. 2012 Jun 15;22(12):4117-21. doi: 10.1016/j.bmcl.2012.04.061. Epub 2012 Apr 21.

PMID:
22572578
31.

Reprogramming ventricular sensing to suppress electromyographic noise is ill-advised in the operative setting.

Cross DA.

Anesth Analg. 2012 Feb;114(2):479; author reply 481-2. doi: 10.1213/ANE.0b013e31823f0d3d. No abstract available.

PMID:
22266701
32.

Transmitting and processing electronic prescriptions: experiences of physician practices and pharmacies.

Grossman JM, Cross DA, Boukus ER, Cohen GR.

J Am Med Inform Assoc. 2012 May-Jun;19(3):353-9. doi: 10.1136/amiajnl-2011-000515. Epub 2011 Nov 18.

33.

Analysis of 1ω bulk laser damage in KDP.

Cross DA, Carr CW.

Appl Opt. 2011 Aug 1;50(22):D7-11. doi: 10.1364/AO.50.0000D7.

PMID:
21833093
34.

Exploration of the multiparameter space of nanosecond-laser damage growth in fused silica optics.

Negres RA, Liao ZM, Abdulla GM, Cross DA, Norton MA, Carr CW.

Appl Opt. 2011 Aug 1;50(22):D12-20. doi: 10.1364/AO.50.000D12.

PMID:
21833091
35.

The effect of laser pulse shape and duration on the size at which damage sites initiate and the implications to subsequent repair.

Carr CW, Cross DA, Norton MA, Negres RA.

Opt Express. 2011 Jul 4;19 Suppl 4:A859-64. doi: 10.1364/OE.19.00A859.

PMID:
21747555
36.

Physician practices, e-prescribing and accessing information to improve prescribing decisions.

Grossman JM, Boukus ER, Cross DA, Cohen GR.

Res Brief. 2011 May;(20):1-10.

PMID:
21545050
37.

Multiples of minimal alveolar concentration of volatile agents are not necessarily equipotent.

Cross DA.

Anesthesiology. 2011 Jan;114(1):221; author reply 221-2. doi: 10.1097/ALN.0b013e3181fef395. No abstract available.

PMID:
21178681
38.

Growth behavior of laser-induced damage on fused silica optics under UV, ns laser irradiation.

Negres RA, Norton MA, Cross DA, Carr CW.

Opt Express. 2010 Sep 13;18(19):19966-76. doi: 10.1364/OE.18.019966.

PMID:
20940888
39.

ERK5 is required for VEGF-mediated survival and tubular morphogenesis of primary human microvascular endothelial cells.

Roberts OL, Holmes K, Müller J, Cross DA, Cross MJ.

J Cell Sci. 2010 Sep 15;123(Pt 18):3189-200. doi: 10.1242/jcs.072801. Epub 2010 Aug 24. Erratum in: J Cell Sci. 2010 Oct 1;123(Pt 19):3413.

40.
41.

ERK5 and the regulation of endothelial cell function.

Roberts OL, Holmes K, Müller J, Cross DA, Cross MJ.

Biochem Soc Trans. 2009 Dec;37(Pt 6):1254-9. doi: 10.1042/BST0371254. Review.

PMID:
19909257
42.

FRAT1, a substrate-specific regulator of glycogen synthase kinase-3 activity, is a cellular substrate of protein kinase A.

Hagen T, Cross DA, Culbert AA, West A, Frame S, Morrice N, Reith AD.

J Biol Chem. 2006 Nov 17;281(46):35021-9. Epub 2006 Sep 18.

43.

pKa of fentanyl varies with temperature: implications for acid-base management during extremes of body temperature.

Thurlkill RL, Cross DA, Scholtz JM, Pace CN.

J Cardiothorac Vasc Anesth. 2005 Dec;19(6):759-62.

PMID:
16326301
45.

Comparison of perceived pain with different immobilization techniques.

Cross DA, Baskerville J.

Prehosp Emerg Care. 2001 Jul-Sep;5(3):270-4.

PMID:
11446541
46.

Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death.

Cross DA, Culbert AA, Chalmers KA, Facci L, Skaper SD, Reith AD.

J Neurochem. 2001 Apr;77(1):94-102.

47.

Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription.

Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ, Rausch OL, Murphy GJ, Carter PS, Roxbee Cox L, Mills D, Brown MJ, Haigh D, Ward RW, Smith DG, Murray KJ, Reith AD, Holder JC.

Chem Biol. 2000 Oct;7(10):793-803.

48.

ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK.

Hall-Jackson CA, Cross DA, Morrice N, Smythe C.

Oncogene. 1999 Nov 18;18(48):6707-13.

50.

PDK1, one of the missing links in insulin signal transduction?

Cohen P, Alessi DR, Cross DA.

FEBS Lett. 1997 Jun 23;410(1):3-10. Review.

Supplemental Content

Loading ...
Support Center